Ixchiq (VLA1553) / Valneva 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  VLA1553 / Valneva
    Cost-Effectiveness of Chikungunya Vaccination With IXCHIQ in Adults in Puerto Rico () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1593;    
    The IXCHIQ vaccination program is cost-effective for adults aged ?18 years in Puerto Rico, when assessing the likelihood of an outbreak within the next 20 years. The findings support recommending the IXCHIQ vaccine to mitigate the public health impact of CHIKV in this population, with robust results confirmed across multiple analyses.
  • ||||||||||  VLA1553 / Valneva, PXVX0317 / Bavarian Nordic
    Preclinical, Review, Journal:  Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure. (Pubmed Central) -  Nov 2, 2024   
    These vaccines use messenger RNA-lipid nanoparticles, inactivated virus, and viral vector approaches, with a live-attenuated vaccine VLA1553 and a virus-like particle PXVX0317 in phase III testing. The European Medicine Agency is considering accelerated assessment review of PXVX0317, with potential for approval by both agencies in 2025.
  • ||||||||||  VLA1553 / Valneva
    Modelling of 5 year antibody persistence after vaccination with Live attenuated Chikungunya vaccine VLA1553 (IXCHIQ (Convention Center - Hall I-1 (1st Floor); In-Person-Only) -  Oct 26, 2024 - Abstract #ASTMH2024ASTMH_3946;    
    P3
    These results are encouraging, suggesting that VLA1553 could provide long-term protection against CHIKV, making it a crucial tool for controlling the spread of chikungunya and reducing its public health impact. The ongoing VLA1553-303 clinical trial will be essential to confirm these findings and support the ongoing development of VLA1553.
  • ||||||||||  VLA1553 / Valneva
    Cross-neutralizing antibody responses elicited by the chikungunya vaccine VLA1553 (Convention Center - Hall I-1 (1st Floor); In-Person-Only) -  Oct 26, 2024 - Abstract #ASTMH2024ASTMH_3539;    
    P3
    Finally, we used antigenic cartography to demonstrate vaccinee and infection sera cluster antigenically. These data imply that VLA1553 elicits a cross-nAb breadth that extends to related alphaviruses to a similar potency of CHIKV infection, which may have important cross-protective implications for individuals susceptible to alphavirus cocirculation.
  • ||||||||||  VLA1553 / Valneva
    Predicting the impact of a potential chikungunya outbreak in Miami and the impact of a chikungunya vaccine (Convention Center - Hall I-1 (1st Floor); In-Person-Only) -  Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1266;    
    Our model results show that an emergency response vaccination program can be effective during a CHIKV outbreak, especially if the outbreak is detected early on and the program is initiated promptly after detection. Future research should explore the applicability of these findings in other locations where Aedes mosquitoes are present.
  • ||||||||||  VLA1553 / Valneva
    Cross-neutralizing antibody responses elicited by the chikungunya vaccine VLA1553 (Convention Center - Room 383/384/385 (3rd Floor); In-Person-Only) -  Oct 11, 2024 - Abstract #ASTMH2024ASTMH_965;    
    P3
    Finally, we used antigenic cartography to demonstrate vaccinee and infection sera cluster antigenically. These data imply that VLA1553 elicits a cross-nAb breadth that extends to related alphaviruses to a similar potency of CHIKV infection, which may have important cross-protective implications for individuals susceptible to alphavirus cocirculation.
  • ||||||||||  VLA1553 / Valneva
    Retrospective data, Review, Journal:  Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Sep 29, 2024   
    Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations.
  • ||||||||||  VLA1553 / Valneva
    Cross-neutralizing antibody responses elicited by the chikungunya vaccine VLA1553 (Convention Center - Room 345 (3rd Floor); In-Person-Only) -  Sep 15, 2024 - Abstract #ASTMH2024ASTMH_45;    
    P3
    Finally, we used antigenic cartography to demonstrate vaccinee and infection sera cluster antigenically. These data imply that VLA1553 elicits a cross-nAb breadth that extends to related alphaviruses to a similar potency of CHIKV infection, which may have important cross-protective implications for individuals susceptible to alphavirus cocirculation.
  • ||||||||||  VLA1553 / Valneva
    Trial completion date:  Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) (clinicaltrials.gov) -  Aug 14, 2024   
    P3,  N=363, Active, not recruiting, 
    VLA1553 adds to strategies to reduce the spread and burden of chikungunya in endemic populations and travellers. Trial completion date: Dec 2025 --> May 2031
  • ||||||||||  VLA1553 / Valneva
    Enrollment closed, Trial completion date:  A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents (clinicaltrials.gov) -  Mar 16, 2023   
    P3,  N=750, Active, not recruiting, 
    The strong immune response and the generation of seroprotective titres in almost all vaccinated participants suggests that VLA1553 is an excellent candidate for the prevention of disease caused by chikungunya virus. Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Feb 2024
  • ||||||||||  VLA1553 / Valneva
    Chikungunya: Phase 3 Clinical Development of a Single-shot Live-attenuated Vaccine (Convention Center - Room 618/619/620 (6th Floor); In-Person-Only) -  Oct 9, 2022 - Abstract #ASTMH2022ASTMH_1306;    
    P3
    VLA1553 was also well tolerated with a favourable safety profile. The generation of protective titers in nearly 100% of vaccinated participants analyzed indicates VLA1553 is an effective candidate for the prevention of disease caused by the CHIKV.
  • ||||||||||  VLA1553 / Valneva
    Journal:  Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera. (Pubmed Central) -  Jul 27, 2022   
    In addition, serum transfer protected animals from other CHIKV associated clinical symptoms and from CHIKV persistence in tissue. Based on this passive transfer study, a 50% micro plaque reduction neutralization test titer of ≥150 was determined as a surrogate of protection which was supported by analysis of samples from a sero-epidemiological study.In conclusion, considering the unfeasibility of an efficacy trial due to the unpredictability and explosive, rapidly moving nature of chikungunya outbreaks, the definition of a surrogate of protection for VLA1553 is an important step towards vaccine licensure to reduce the medical burden caused by chikungunya.
  • ||||||||||  VLA1553 / Valneva
    Enrollment open, Trial completion date, Trial primary completion date:  A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents (clinicaltrials.gov) -  Feb 25, 2022   
    P3,  N=750, Recruiting, 
    Based on this passive transfer study, a 50% micro plaque reduction neutralization test titer of ≥150 was determined as a surrogate of protection which was supported by analysis of samples from a sero-epidemiological study.In conclusion, considering the unfeasibility of an efficacy trial due to the unpredictability and explosive, rapidly moving nature of chikungunya outbreaks, the definition of a surrogate of protection for VLA1553 is an important step towards vaccine licensure to reduce the medical burden caused by chikungunya. Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Apr 2023 | Trial primary completion date: Nov 2021 --> May 2022